Thursday, 25 May 2017

You are here

Educational Intervention Facilitates Treat-to-Target Management in Rheumatoid Arthritis

Treat-to-target (TTT) has become a goal in rheumatoid arthritis (RA) therapeutics, but its implementation in daily practice is varied and viewed to be difficult by most. Solomon and coworkers have shown that TTT education through group-based quality improvement sessions can result in wider use of TTT in practice.

They set out to study the adherence to TTT in practice using a randomized quality improvement intervention with wait-list control across 11 rheumatology sites in the US.

The intervention utilized was a "learning collaborative" effort to establish best practices. These group-based learning collaboratives used rapid cycle testing for change along with frequent assessment of quality care improvements.

For 9-months the LC group incorporated rapid-cycle improvement methods. A composite TTT implementation score was a percentage of four required items documented in the chart. These included: 1) a disease activity target; 2) recording RA disease activity,numerically or by category (i.e., remission, low disease activity, etc.) using either the DAS28, SDAI, CDAI, or RAPID3; 3) documenting shared-decision making; and 4) documenting treatment decisions based on target and disease activity measure.

Five sites (23 providers) were randomized to intervention  and managed 320 patients, while six sites (23 provider) were randomized to the wait-list control, managing 321 patients.

At study start a minority utilized TTT with mean TTT implementation score of 11%.  After  9 months, the TTT implementation score was higher with the LC intervention (57% vs 25% in control).

Substantial improvement in TTT utilization was seen with this learning collaborative intervention.  

While nearly half of all rheumatologists utilize some disease measure in practice, there is little evidence that they utilize this information in daily patient management.  These findings suggest that knowing and using the measure in the clinic may not be enough and that a substantial committment to quality care and specific educational interventions are needed to demonstrate treatment decisions based on disease activity measures in RA.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

NLRP3 Activation in Still's Disease

Adult-onset Still disease (AOSD) is usually regarded as an autoinflammatory disease, largely because of its symptomatology and responsiveness to IL-1 inhibition.  Thus while it is assumed that aberrant NLRP3 inflammasome activity underlies active AOSD, the connection between NLRP3 AOSD has yet to be solidfied.

IL-6 Inhibitor Kevzara Granted FDA Approval for Rheumatoid Arthritis

The FDA has approved sarilumab (Kevzara), a new IL-6 inhibotor co-developed by Regeneron and Sanofi's, for use in adults with moderate to severe rheumatoid arthritis (RA).

Although approved in Canada in February 2017, the US submission of the sarilumabs BLA was held up by the FDA with a complete response letter and concerns about manufacturing.

Rituximab May Benefit Rheumatoid Lung

A retrospective study shows that rituximab treatment of RA-related interstitial lung disease may improve or forestall ILD progression.

Increased Comorbidities in Rheumatoid Arthritis

A population based study from Taiwan examined the frequencies of comorbidities in a rheumatoid arthritis (RA) population.

Using the 2010-2012 Korea National Health and Nutrition Examination Survey (KNHANES), researchers determined the weighted prevalence and odds ratio (OR) of comorbidities from a population of 37,453,158) wherin the prevalence of RA was 1.5%.

Enthesitis-Related Arthritis in Children

Enthesitis-related arthritis (ERA) is an emerging subset of juvenile idiopathic arthritis (JIA) recognized for its distinctive clinical characteristics.  ILAR has defined criteria for ERA and Gmuca and colleagues have performed a cross-sectional, multicenter analysis of ERA patients seen between 1989 and 2012.